Research programme: stem cell therapies - NeoStem Oncology

Drug Profile

Research programme: stem cell therapies - NeoStem Oncology

Alternative Names: MotorGraft

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator California Stem Cell; Families of SMA; Johns Hopkins University; University of California at Irvine
  • Developer ALS Therapy Development Institute; Families of SMA; Johns Hopkins University; NeoStem Oncology; University of California at Irvine
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Spinal muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy(In infants) in USA
  • 08 May 2014 NeoStem acquires California Stem Cell and renames it NeoStem Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top